Show simple item record

dc.contributor.authorRanson, JM
dc.contributor.authorBucholc, M
dc.contributor.authorLyall, D
dc.contributor.authorNewby, D
dc.contributor.authorWinchester, L
dc.contributor.authorOxtoby, NP
dc.contributor.authorVeldsman, M
dc.contributor.authorRittman, T
dc.contributor.authorMarzi, S
dc.contributor.authorSkene, N
dc.contributor.authorAl Khleifat, A
dc.contributor.authorFoote, IF
dc.contributor.authorOrgeta, V
dc.contributor.authorKormilitzin, A
dc.contributor.authorLourida, I
dc.contributor.authorLlewellyn, DJ
dc.date.accessioned2023-02-01T10:02:43Z
dc.date.issued2023-02-24
dc.date.updated2023-02-01T09:38:02Z
dc.description.abstractProgress in dementia research has been limited, with substantial gaps in our knowledge of targets for prevention, mechanisms for disease progression, and disease-modifying treatments. The growing availability of multimodal datasets opens possibilities for the application of machine learning and artificial intelligence (AI) to help answer key questions in the field. We provide an overview of the state of the science, highlighting current challenges and opportunities for utilisation of AI approaches to move the field forward in the areas of genetics, experimental medicine, drug discovery and trials optimisation, imaging, and prevention. Machine learning methods can enhance results of genetic studies, help determine biological effects and facilitate the identification of drug targets based on genetic and transcriptomic information. The use of unsupervised learning for understanding disease mechanisms for drug discovery is promising, while analysis of multimodal datasets to characterise and quantify disease severity and subtype are also beginning to contribute to optimisation of clinical trial recruitment. Data-driven experimental medicine is needed to analyse data across modalities and develop novel algorithms to translate insights from animal models to human disease biology. AI methods in neuroimaging outperform traditional approaches for diagnostic classification and although challenges around validation and translation remain, there is optimism for their meaningful integration to clinical practice in the near future. AI-based models can also clarify our understanding of the causality and commonality of dementia risk factors, informing and improving risk prediction models along with the development of preventative interventions. The complexity and heterogeneity of dementia requires an alternative approach beyond traditional design and analytical approaches. Although not yet widely used in dementia research, machine learning and AI have the potential to unlock current challenges and advance precision dementia medicine.en_GB
dc.description.sponsorshipAlan Turing Instituteen_GB
dc.description.sponsorshipNational Institute on Agingen_GB
dc.description.sponsorshipUKRIen_GB
dc.description.sponsorshipMotor Neurone Disease Associationen_GB
dc.description.sponsorshipAlzheimer’s Research UKen_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.description.sponsorshipALS Associationen_GB
dc.description.sponsorshipCambridge Centre for Parkinson's Plus Disordersen_GB
dc.description.sponsorshipCambridge Biomedical Research Centreen_GB
dc.description.sponsorshipDr George Moore Endowment for Data Science, Ulster Universityen_GB
dc.description.sponsorshipGeorge Henry Woolfe Legacy Funden_GB
dc.description.sponsorshipEngineering and Physical Sciences Research Council (EPSRC)
dc.description.sponsorshipNational Institutes of Health
dc.identifier.citationVol. 10, article 6en_GB
dc.identifier.doi10.1186/s40708-022-00183-3
dc.identifier.grantnumberEP/N510129/1en_GB
dc.identifier.grantnumberRF1AG055654en_GB
dc.identifier.grantnumberMR/S03546X/1en_GB
dc.identifier.grantnumberAl Khleifat/Oct21/975-799en_GB
dc.identifier.urihttp://hdl.handle.net/10871/132385
dc.identifierORCID: 0000-0001-9491-3940 (Ranson, Janice)
dc.language.isoenen_GB
dc.publisherSpringerOpenen_GB
dc.rights© The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
dc.subjectdementiaen_GB
dc.subjectartificial intelligenceen_GB
dc.subjectmachine learningen_GB
dc.subjectgeneticsen_GB
dc.subjectdrug discoveryen_GB
dc.subjectneuroimagingen_GB
dc.subjectpreventionen_GB
dc.subjectiPSCen_GB
dc.subjectanimal modelsen_GB
dc.titleHarnessing the potential of machine learning and artificial intelligence for dementia researchen_GB
dc.typeArticleen_GB
dc.date.available2023-02-01T10:02:43Z
dc.identifier.issn2198-4018
dc.descriptionThis is the final version. Available on open access from SpringerOpen via the DOI in this recorden_GB
dc.descriptionData availability: Data sharing is not applicable to this review article as no new data were created or analysed in this study.en_GB
dc.identifier.eissn2198-4026
dc.identifier.journalBrain Informaticsen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2022-12-26
dcterms.dateSubmitted2022-05-31
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2022-12-26
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2023-02-01T09:38:05Z
refterms.versionFCDAM
refterms.dateFOA2023-03-03T16:11:54Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
Except where otherwise noted, this item's licence is described as © The Author(s) 2023. Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.